Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35621690)
Watch
English
Hepatitis B virus resistance to antivirals: clinical implications and management.
scientific article published on January 2003
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14708691
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 November 2019
review article
1 reference
stated in
Europe PubMed Central
title
Hepatitis B virus resistance to antivirals: clinical implications and management
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14708691
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 November 2019
main subject
Hepatitis B virus
1 reference
based on heuristic
inferred from title
hepatitis B
1 reference
based on heuristic
inferred from title
author
Fabien Zoulim
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14708691
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 November 2019
author name string
Fabien Zoulim
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14708691
retrieved
9 August 2017
publication date
1 January 2003
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14708691
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 November 2019
published in
Journal of Hepatology
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14708691
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 November 2019
volume
39 Suppl 1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14708691
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 November 2019
page(s)
S133-8
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14708691
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 November 2019
cites work
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lamivudine as initial treatment for chronic hepatitis B in the United States
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Management of hepatitis B: 2000--summary of a workshop
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B viral resistance: mechanisms and diagnosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term therapy of chronic hepatitis B with lamivudine.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination therapy for chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0168-8278(03)00312-X
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14708691
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 November 2019
PubMed publication ID
14708691
1 reference
stated in
Europe PubMed Central
PubMed publication ID
14708691
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 November 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
